Anika Therapeutics, Inc.
ANIK
$9.05
$0.688.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.22M | 26.17M | 30.60M | 38.75M | 30.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.22M | 26.17M | 30.60M | 38.75M | 30.72M |
| Cost of Revenue | 13.86M | 11.49M | 12.87M | 37.31M | 10.24M |
| Gross Profit | 14.36M | 14.68M | 17.73M | 1.44M | 20.49M |
| SG&A Expenses | 12.23M | 12.91M | 11.32M | 19.11M | 15.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.40M | 30.45M | 30.70M | 63.67M | 32.53M |
| Operating Income | -4.18M | -4.28M | -100.00K | -24.92M | -1.81M |
| Income Before Tax | -3.97M | -3.87M | 38.00K | -27.61M | -1.22M |
| Income Tax Expenses | 681.00K | 89.00K | 2.52M | 2.31M | 1.33M |
| Earnings from Continuing Operations | -4.65M | -3.96M | -2.49M | -29.92M | -2.54M |
| Earnings from Discontinued Operations | 677.00K | -915.00K | -19.38M | -- | 2.45M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.97M | -4.87M | -21.87M | -29.92M | -88.00K |
| EBIT | -4.18M | -4.28M | -100.00K | -24.92M | -1.81M |
| EBITDA | -2.76M | -2.69M | 2.09M | -22.73M | 248.00K |
| EPS Basic | -0.28 | -0.34 | -1.50 | -2.03 | -0.01 |
| Normalized Basic EPS | -0.17 | -0.17 | 0.03 | -1.04 | -0.05 |
| EPS Diluted | -0.28 | -0.34 | -1.50 | -2.03 | -0.01 |
| Normalized Diluted EPS | -0.17 | -0.17 | 0.03 | -1.04 | -0.05 |
| Average Basic Shares Outstanding | 14.36M | 14.30M | 14.58M | 14.77M | 14.84M |
| Average Diluted Shares Outstanding | 14.52M | 14.30M | 14.62M | 14.77M | 14.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |